Clinical Evidence: SAC® & Bone Health

A Potent Calcium Dietary Intervention Helps Improve Bone Mineral Density

Published in Journal of Family Medicine and Primary Care – Open Access (Gavin Publishers)

Clinical Evidence Summary

DOI: 10.29011/2688-7460.100290
Study Type: Retrospective Clinical Investigation
Population: 82 Asian Older Adults
Duration: Approximately 8 months
Intervention: Sigma Anti-bonding Calcium Carbonate (SAC®) (Gavin Publishers)
Primary Outcomes: Bone mineral density (BMD), T-score, speed of sound (SOS)
Key Findings: Statistically significant improvements in BMD, T-score, and SOS (p < 0.0001)

Results:

  • BMD ↑ from 0.95 → 1.10 g/cm² (p < 0.0001)
  • T-score ↑ from –2.0 → –0.85 (p < 0.0001)
Bar chart showing significant improvements in bone mineral density after approximately 8 months of SAC® supplementation across all participants, osteopenia, and osteoporosis groups, alongside key clinical findings including BMD increase from 0.95 to 1.10 g/cm², T-score from −2.0 to −0.85, and speed of sound from 3,946 to 4,079 in an 82-participant study.

Comparison of changes in Bone Mineral Density after 8 months of SAC®

Key Takeaways

Clinically Significant Improvements in Bone Health

Across all participants, daily SAC® supplementation resulted in statistically significant improvements in:

  • Bone Mineral Density (BMD): from 0.95 → 1.10 g/cm² (p < 0.0001)
  • T-score: from –2.0 → –0.85 (p < 0.0001)
  • Speed of Sound (SOS): from 3,946 → 4,079 (p < 0.0001) (Gavin Publishers)

These changes are consistent across genders and age groups. (Gavin Publishers).

 

Clinical Group Outcomes:
What Changed?

Post-intervention classification shifts:

Clinical Group Outcome After ~8 Months

Osteopenia

65% shifted to normal range

Osteoporosis

64% shifted to osteopenia

Baseline Osteoporosis → Normal

12% transitioned to normal
Clinical group outcome shifts after approximately 8 months of SAC® supplementation showing 65% of osteopenia participants transitioning to normal bone density, 64% of osteoporosis participants transitioning to osteopenia, and 12% of baseline osteoporosis participants reaching normal, based on an 82-participant clinical study.

Clinical Study Data: 82 Participants (Gavin Publishers)

Study Design at a Glance
Participants‘s icon

Participants

  • 82 adults stratified by baseline T-score

 

Intervention's icon

Intervention

  • Daily SAC® (7.6 mg), dissolved in water twice daily
  • Administered ~8 months
  • Bone health measured via portable ultrasound (distal radius) (Gavin Publishers)

 

Endpoints Assessed's icon

Endpoints Assessed

  • Bone Mineral Density (BMD)
  • T-score (standardized comparison to healthy young adults)
  • Speed of Sound (SOS) — validated proxy for peripheral bone strength (Gavin Publishers)
Clinical study results showing statistically significant improvements in bone mineral density, T-scores, and ultrasound-based bone strength metrics following daily SAC® calcium supplementation in older adults.

Clinical outcomes after ~8 months of daily SAC® supplementation

Comparison of baseline and post-intervention T-scores demonstrating improvement in bone density classification following approximately eight months of SAC® calcium intake；Distribution of participants transitioning from osteoporosis to osteopenia and from osteopenia to normal bone density after SAC® calcium supplementation, based on clinical ultrasound measurements.

Bone mineral density (BMD) increased after SAC® supplementation, with greater gains observed in men than women and in menopausal than non-menopausal women.

Why These Results Matter
  • SAC® showed broad efficacy across normal, osteopenic, and osteoporotic individuals. (Gavin Publishers)
  • Improvements were independent of age and gender, though some gender subgroup differences were noted in effect size. (Gavin Publishers)
  • Results suggest bioavailability and calcium signaling enhancements compared to conventional calcium carbonate. (Gavin Publishers)
  • Menopausal group showed higher improvement compared to the non-menopausal female group (15.15% vs. 8.11%, p=0.028).(Gavin Publishers)

These outcomes may translate into meaningful reductions in fracture risk with longer follow-up, though definitive fracture endpoints were not measured. (Gavin Publishers)

Mechanism: What Makes SAC® Different?

Conventional calcium supplements require vitamin D for absorption and have variable bioavailability. In contrast, Sigma Anti-bonding Calcium Carbonate (SAC®):

  • Exhibits weaker sigma antibonding, increasing solubility.
  • Enables more ionized, bioactive calcium to enter circulation.
  • Supports osteoblast differentiation and bone formation via BMP signaling. (Gavin Publishers)

Safety & Tolerability

No adverse events were reported in the study cohort during the ~8-month intervention. Daily administration was well tolerated. (Gavin Publishers)

Study Limitations

To contextualize these promising results:

  • Retrospective design: not a randomized controlled trial (RCT)
  • Ultrasound measurements: while cost-effective, are less standard than DXA
  • Population: Majority East Asian participants; broader applicability needs confirmation (Gavin Publishers)

Future prospective RCTs with DXA and fracture outcomes are warranted. (Gavin Publishers)

Clinical Interpretation

Daily SAC® calcium supplementation showed significant improvements in bone density metrics across a real-world older adult cohort, shifting a majority of osteopenic and osteoporotic participants toward healthier bone status. These findings provide credible, peer-reviewed evidence supporting SAC® as a bioavailable calcium intervention for bone health optimization. (Gavin Publishers)

Download Full Study

Accessible via open-access journal repository.

All numerical values, statistical results, and outcome descriptions on this page are derived directly from the published manuscript. The data summarized on this page is derived from a peer-reviewed clinical study published in an open-access medical journal. All numerical outcomes, statistical values, and clinical interpretations are sourced directly from the published manuscript.

How to Cite This Pagey

Recommended Citation:

Marah Natural. Clinical Evidence: SAC® Calcium and Bone Mineral Density. Based on: Journal of Family Medicine and Primary Care. DOI: 10.29011/2688-7460.100290)

Clinical Evidence: SAC® & Bone Health

A Potent Calcium Dietary Intervention Helps Improve Bone Mineral Density

Published in Journal of Family Medicine and Primary Care – Open Access (Gavin Publishers)

Clinical Evidence Summary

DOI: 10.29011/2688-7460.100290
Study Type: Retrospective Clinical Investigation
Population: 82 Asian Older Adults
Duration: Approximately 8 months
Intervention: Sigma Anti-bonding Calcium Carbonate (SAC®) (Gavin Publishers)
Primary Outcomes: Bone mineral density (BMD), T-score, speed of sound (SOS)
Key Findings: Statistically significant improvements in BMD, T-score, and SOS (p < 0.0001)

Results:

  • BMD ↑ from 0.95 → 1.10 g/cm² (p < 0.0001)
  • T-score ↑ from –2.0 → –0.85 (p < 0.0001)
Key Takeaways

Clinically Significant Improvements in Bone Health

Across all participants, daily SAC® supplementation resulted in statistically significant improvements in:

  • Bone Mineral Density (BMD): from 0.95 → 1.10 g/cm² (p < 0.0001)
  • T-score: from –2.0 → –0.85 (p < 0.0001)
  • Speed of Sound (SOS): from 3,946 → 4,079 (p < 0.0001) (Gavin Publishers)

These changes are consistent across genders and age groups. (Gavin Publishers).

Comparison of changes in Bone Mineral Density after 8 months of SAC®

Clinical Group Outcomes:
What Changed?

Post-intervention classification shifts:

Clinical Group Outcome After ~8 Months

Osteopenia

65% shifted to normal range

Osteoporosis

64% shifted to osteopenia

Baseline Osteoporosis → Normal

12% transitioned to normal

Clinical Study Data: 82 Participants (Gavin Publishers)

Study Design at a Glance

Participants

  • 82 adults stratified by baseline T-score

Intervention

  • Daily SAC® (7.6 mg), dissolved in water twice daily
  • Administered ~8 months
  • Bone health measured via portable ultrasound (distal radius) (Gavin Publishers)

Endpoints Assessed

  • Bone Mineral Density (BMD)
  • T-score (standardized comparison to healthy young adults)
  • Speed of Sound (SOS) — validated proxy for peripheral bone strength (Gavin Publishers)

Clinical outcomes after ~8 months of daily SAC® supplementation

Why These Results Matter
  • SAC® showed broad efficacy across normal, osteopenic, and osteoporotic individuals. (Gavin Publishers)
  • Improvements were independent of age and gender, though some gender subgroup differences were noted in effect size. (Gavin Publishers)
  • Results suggest bioavailability and calcium signaling enhancements compared to conventional calcium carbonate. (Gavin Publishers)
  • Menopausal group showed higher improvement compared to the non-menopausal female group (15.15% vs. 8.11%, p=0.028).(Gavin Publishers)

These outcomes may translate into meaningful reductions in fracture risk with longer follow-up, though definitive fracture endpoints were not measured. (Gavin Publishers)

Bone mineral density (BMD) increased after SAC® supplementation, with greater gains observed in men than women and in menopausal than non-menopausal women.

Mechanism: What Makes SAC® Different?

Conventional calcium supplements require vitamin D for absorption and have variable bioavailability. In contrast, Sigma Anti-bonding Calcium Carbonate (SAC®):

  • Exhibits weaker sigma antibonding, increasing solubility.
  • Enables more ionized, bioactive calcium to enter circulation.
  • Supports osteoblast differentiation and bone formation via BMP signaling. (Gavin Publishers)

Safety & Tolerability

No adverse events were reported in the study cohort during the ~8-month intervention. Daily administration was well tolerated. (Gavin Publishers)

Study Limitations

To contextualize these promising results:

  • Retrospective design: not a randomized controlled trial (RCT)
  • Ultrasound measurements: while cost-effective, are less standard than DXA
  • Population: Majority East Asian participants; broader applicability needs confirmation (Gavin Publishers)

Future prospective RCTs with DXA and fracture outcomes are warranted. (Gavin Publishers)

Clinical Interpretation

Daily SAC® calcium supplementation showed significant improvements in bone density metrics across a real-world older adult cohort, shifting a majority of osteopenic and osteoporotic participants toward healthier bone status. These findings provide credible, peer-reviewed evidence supporting SAC® as a bioavailable calcium intervention for bone health optimization. (Gavin Publishers)

Download Full Study

Accessible via open-access journal repository.

All numerical values, statistical results, and outcome descriptions on this page are derived directly from the published manuscript. The data summarized on this page is derived from a peer-reviewed clinical study published in an open-access medical journal. All numerical outcomes, statistical values, and clinical interpretations are sourced directly from the published manuscript.

How to Cite This Pagey

Recommended Citation:

Marah Natural. Clinical Evidence: SAC® Calcium and Bone Mineral Density. Based on: Journal of Family Medicine and Primary Care. DOI: 10.29011/2688-7460.100290)